RICHMOND, British Columbia, June 2, 2011 (GLOBE NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today that it has contracted the services of CaroLink Science Solutions to help expedite the FDA approval of its RECAF™ cancer marker test and to compile the large amount of data acquired by BioCurex for publication in peer-reviewed medical journals. Unlike other notable cancer markers that only detect the presence of a specific cancer type (CEA for colon cancer and PSA for prostate cancer), RECAF is found on most types of cancer and, therefore, could have a much broader use than most other cancer markers currently under development or in use today. Moreover, unlike existing cancer markers, RECAF has been shown to detect early stages of breast and prostate cancers when the likelihood of a cure is the highest.
CaroLink Science Solutions is a one-stop consulting company that provides tailored teams of scientific and business development experts to deliver top quality, innovative and cost-effective full cycle consulting solutions to address the scientific, technical, regulatory and business development challenges confronting its clients. Clients include biotechnology, biomedical device, pharmaceutical, cosmetics and food companies, healthcare, academic and educational institutions, lawyers, investors, financial institutions, insurance and government entities.
BioCurex's President and CEO, Dr. Ricardo Moro-Vidal said, "The experts at CaroLink Science Solutions have successfully managed regulatory approvals with the FDA, Health Canada, European and other international regulatory bodies and we are pleased to welcome them to the BioCurex team. As a result of rising costs, we believe that there is a demand for more cost-effective approaches to disease management, specifically for cancer, as well as for an emphasis on screening and accurate diagnostic testing to facilitate early detection of potentially life threatening and costly afflictions. Together with the collaboration of CaroLink Science Solutions, we are confident that our cancer marker test can soon be submitted for marketing approval to the FDA."
BioCurex noted that 510(k) applications are processed by the FDA within 90 days of the submission date.
Moro-Vidal added, "We believe that the collaboration with CaroLink Science Solutions will be very valuable, and by working closely together, we shall significantly enhance our efforts to achieve our 510(k) filing with the FDA on a timely basis."
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF™.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Alere (NYSE:ALR), formerly Inverness Medical Innovations (NYSE:IMA). For further information on these agreements visit: .
For more information about BioCurex, please visit .
For more information about OncoPet Diagnostics Inc., please visit: .
For more information about CaroLink Science Solutions, please visit
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
CONTACT: Investor Relations Contact: DC Consulting (407) 792-3333 firstname.lastname@example.org